Drug Prices

  • |

    The Drug-Price Mystery Has a Lobbying Budget

    ByPhil McCracken

    Patients receive a prescription bill written like a ransom note from an accountant, while the pharmaceutical industry’s Washington invoice arrives in plain English. Bloomberg Government reported that PhRMA spent $7.4 million lobbying in the second quarter of 2026, bringing its year-to-date total to $19.6 million. I have seen less money spent renovating an entire Capitol Hill office, although admittedly fewer people were trying to influence the rulebook.

    That spending does not, by itself, prove that lobbying caused any particular drug price or defeated any particular proposal. It does reveal something less mysterious: the trade group representing major pharmaceutical interests has a very clear budget for being present while everyone else debates why medicine costs so much. When an industry spends millions to participate in the policy conversation, “expertise” starts looking a lot like a reserved seat with better coffee.

    The timing is the whole money trail. Washington continued debating Medicare negotiation, most-favored-nation pricing, and other proposals aimed at lowering costs. Those are policy arguments, not settled outcomes, and they deserve scrutiny on their details. But patients are routinely told that drug pricing is too complex for ordinary people to understand, just as the people affected by the bill are asked to wait outside the room while well-funded representatives explain the machinery.

    That is the access economy in its natural habitat: the public gets a maze of rebates, formularies, negotiations, and carefully polished explanations; lobbyists get calendars, meetings, and a professional vocabulary for turning private interests into public homework. The pharmaceutical lobbying total reported by Bloomberg Government is not the entire industry’s spending, and it is not evidence of illegal conduct. It is simply a large, legible number attached to an argument that is often presented as impossibly complicated.

    So Washington keeps searching for the missing answer to drug prices. Meanwhile, the money trail has already found the billing department. Patients get the mystery, lobbyists get the appointment calendar, and taxpayers get another explanation for why reform remains under review.

    Sources

  • |

    Medicare’s Taxpayer-Funded Layaway Plan

    ByHarlan Quill

    At the courthouse-basement level of policy math, the arrangement is hard to defend: taxpayers help absorb the early risk of medical discovery, then a private patent can put the finished medicine behind a padlock while Medicare and patients meet the checkout price.

    That is a taxpayer-funded layaway plan. We help finance the scientific groundwork, a company controls the bottle, and the public returns to retrieve its medicine with a bill wearing a shareholder-return hat. If public support helps make a breakthrough possible, public policy should at least ask what public value comes back. Otherwise, we did not merely buy the breakthrough; we rented it back from the company that put a padlock on the bottle.

  • |

    If Prices Can Fall Now, Who Approved the Old Ones?

    ByHarlan Quill

    I have spent enough time with budgets to know that when a Medicare drug price falls after negotiation, the old price deserves an audit—not a standing ovation. The usual sales pitch says Medicare must accept whatever number arrives in the envelope, as though drug pricing were a weather event and not a market with lawyers. Then bargaining happens, the bill gets smaller, and “impossible” suddenly develops a discount code.

    The exact before-and-after figures may be illustrative, and lower prices do not automatically shrink every patient’s copay. But the practical point survives the fine print: negotiation can reduce public spending and may ease the bill at the pharmacy counter. The people defending the old system now have to explain why savings were forbidden until someone asked for them. The national drug-pricing spreadsheet has ruled that “unavoidable” was apparently the premium tier, complete with a lobbyist and no cancellation button.

End of content

End of content